Literature DB >> 1784840

Inhibition of arylsulfatase B by ascorbic acid.

L A Selvidge1, A J Verlangieri.   

Abstract

One hypothesis for atherosclerotic lesion formation is the response to injury hypothesis. If catabolism of the ground substance of the intima of blood vessels is viewed as an injury, then inhibition of this catabolism could lead to a decrease in atherosclerotic lesions. Arylsulfatase B catalyses the desulfation of glycosaminoglycans in the catabolism of the intimal ground substance. We have found that ascorbic acid inhibits arylsulfatase B (Km = 2.06 mM, KI = 4.89 mM), thus providing a possible mechanism by which ascorbic acid may decrease atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1784840

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  2 in total

1.  Two distinct uptake mechanisms for ascorbate and dehydroascorbate in human lymphoblasts and their interaction with glucose.

Authors:  F C Ngkeekwong; L L Ng
Journal:  Biochem J       Date:  1997-05-15       Impact factor: 3.857

2.  Upregulation of arylsulfatase B in carotid atherosclerosis is associated with symptoms of cerebral embolization.

Authors:  Erik Biros; Corey S Moran; Jane Maguire; Elizabeth Holliday; Christopher Levi; Jonathan Golledge
Journal:  Sci Rep       Date:  2017-06-28       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.